Surprisingly, the clinical use of anti-IL6 and anti-IL6Rα agent have been limited to rheumatoid arthritis, Castleman’s disease, and systemic juvenile idiopathic arthritis – all of which have been shown to rely largely on the pro-inflammatory effects of IL6 signaling in driving pathogenicity. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.